Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.

Matsumoto K, Niwa N, Hagiwara M, Kosaka T, Tanaka N, Takeda T, Morita S, Mizuno R, Shinojima T, Hara S, Asanuma H, Oya M.

World J Urol. 2019 Sep 26. doi: 10.1007/s00345-019-02970-w. [Epub ahead of print]

PMID:
31559475
2.

Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.

Matsumoto K, Mizuno R, Tanaka N, Ide H, Hasegawa M, Ishida M, Hayakawa N, Yasumizu Y, Hagiwara M, Hara S, Kikuchi E, Miyajima A, Nakagawa K, Nakajima Y, Nakamura S, Nakashima J, Oya M.

Med Oncol. 2014 Jul;31(7):45. doi: 10.1007/s12032-014-0045-1. Epub 2014 Jun 10.

PMID:
24913809
3.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
4.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-733. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
5.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559
6.

Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.

Park JW, Jang WS, Koh DH, Ham WS, Rha KH, Hong SJ, Choi YD.

Yonsei Med J. 2018 Jul;59(5):580-587. doi: 10.3349/ymj.2018.59.5.580.

7.

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.

Taguchi S, Fukuhara H, Azuma T, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Kume H, Igawa Y, Homma Y.

BMC Urol. 2014 Oct 16;14:81. doi: 10.1186/1471-2490-14-81.

8.

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.

Kang YJ, Jang WS, Kwon JK, Yoon CY, Lee JY, Ham WS, Choi YD.

BMC Cancer. 2017 Nov 23;17(1):789. doi: 10.1186/s12885-017-3775-6.

9.

Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.

Taguchi S, Shiraishi K, Fukuhara H, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y.

Int J Clin Oncol. 2016 Oct;21(5):975-980. Epub 2016 Apr 20.

PMID:
27098807
10.

Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.

Kumar A, Samavedi S, Mouraviev V, Bates AS, Coelho RF, Rocco B, Patel VR.

J Robot Surg. 2017 Mar;11(1):37-45. doi: 10.1007/s11701-016-0606-8. Epub 2016 May 31.

PMID:
27245233
11.

Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.

Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML.

Mayo Clin Proc. 2007 Apr;82(4):422-7.

PMID:
17418069
12.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
13.

Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy.

Donin NM, Laze J, Zhou M, Ren Q, Lepor H.

Urology. 2013 Jul;82(1):148-52. doi: 10.1016/j.urology.2013.03.054. Epub 2013 May 22.

PMID:
23706588
14.

Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.

Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ.

Eur Urol. 2014 Aug;66(2):204-10. doi: 10.1016/j.eururo.2013.08.022. Epub 2013 Aug 20.

PMID:
24007712
15.

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.

Simmons MN, Stephenson AJ, Klein EA.

Eur Urol. 2007 May;51(5):1175-84. Epub 2007 Jan 12. Review.

PMID:
17240528
16.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM.

JAMA. 2004 Mar 17;291(11):1325-32.

PMID:
15026399
17.

Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.

Malik RD, Goldberg JD, Hochman T, Lepor H.

Eur Urol. 2011 Sep;60(3):548-53. doi: 10.1016/j.eururo.2011.05.036. Epub 2011 May 26.

PMID:
21652145
18.

Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.

Eur Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.

PMID:
24345725
19.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

20.

Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.

Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y.

J Urol. 2003 Aug;170(2 Pt 1):447-50.

PMID:
12853796

Supplemental Content

Support Center